Last reviewed · How we verify
Placebo to valsartan
This is a placebo control, not an active drug, and therefore has no pharmacological mechanism.
At a glance
| Generic name | Placebo to valsartan |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active comparator (valsartan). It produces no direct molecular or physiological effect beyond potential placebo response. This entry represents the control arm in comparative studies of valsartan.
Approved indications
Common side effects
Key clinical trials
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (PHASE1)
- A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (PHASE2)
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction (PHASE2)
- Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (PHASE3)
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to valsartan CI brief — competitive landscape report
- Placebo to valsartan updates RSS · CI watch RSS
- Novartis portfolio CI